In intensive care medicine, various plasma proteins from Biotest are already in use today, for instance as volume and protein replacement in severe injuries and burns and also for the treatment of severe bacterial infections (e.g. sepsis).
Continuing this practice, Biotest is developing the IgM and IgA-enriched polyclonal antibody preparation trimodulin for the treatment of severe community acquired pneumonia.
Moreover, we are developing an innovative fibrinogen concentrate, used amongst others to treat life-threatening bleedings.
